"Based on these encouraging preclinical data, we believe ASC37 has the potential to be a first-in-class once-monthly SQ triple peptide agonist for people living with severe obesity, also with the added advantage of being submitted under the BLA regulatory process," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis
Klinic verifies your benefits right before your first visit
One of the most modern drug classes available that is able to achieve both glycemic control and weight loss are glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs)
To date, no regulated human trials have been conducted looking into the risks
How much water should you drink on Mounjaro to stay properly hydrated
PlexusDx offers both compounded semaglutide injection (at $189/mo month-to-month, or from $149/mo on the 6-month plan) and oral semaglutide (at $289/mo month-to-month, or from $249/mo on the 6-month plan) from licensed 503A pharmacies